Neuropsychopharmacology www.nature.com/npp

CORRECTION

Correction: Optimizing psychedelic compounds for neuropsychiatric therapy

Scott M. Thompson

Neuropsychopharmacology (2021) 46:1545; https://doi.org/10.1038/s41386-021-01021-6

Correction to: *Neuropsychopharmacology* https://doi.org/10.1038/s41386-021-01004-7, published online 05 April 2021

The original version of this article unfortunately mischaracterized the pharmacology of ibogaine.

The corrected text is as follows:

The recent report in *Nature* from Cameron et al. (2021)[4] offers tantalizing evidence that non-hallucinogenic psychedelic compounds may possess beneficial actions. The authors started with ibogaine, a powerful hallucinogenic plant alkaloid with low affinity for serotonin and dopamine transporters, as well as kappa opioid receptors[4,5]. They then synthesized a novel analog of ibogaine called tabernanthalog (TBG). TBG is shown to have unique pharmacological properties and to lack many of the negative side effects of ibogaine.

Published online: 5 May 2021